All In Biotech

Drug Trial Radar · NCT07232719

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Nov 17, 2025

Primary completion

Jun 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits. Participants who complete the primary 56-week GZQJ study will have the opportunity to receive an additional 52 weeks of treatment with retatrutide.

Conditions

  • Obesity
  • Overweight

Interventions

  • RetatrutideDrug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in Body WeightTime frame: Baseline, Week 56

Locations

31 sites in 2 countries. Site status is shown where the registry gives one.

  • Artemis Institute for Clinical Research

    Riverside, California

  • JEM Research Institute

    Atlantis, Florida

  • Headlands Research Orlando

    Orlando, Florida

  • Care Access - Tamarac

    Tamarac, Florida

  • Care Access - Arlington Heights

    Arlington Heights, Illinois

  • L-MARC Research Center

    Louisville, Kentucky

  • IMA Clinical Research Monroe - Armand

    Monroe, Louisiana

  • Pharmasite Research, Inc.

    Baltimore, Maryland

  • Clinical Research Professionals

    Chesterfield, Missouri

  • Clinvest Headlands Llc

    Springfield, Missouri

  • IMA Clinical Research Warren

    Warren Township, New Jersey

  • IMA Clinical Research Manhattan

    New York, New York

  • Trial Management Associates - Wilmington - Floral Parkway

    Wilmington, North Carolina

  • Cedar Health Research

    Dallas, Texas

  • Headlands Research-El Paso

    El Paso, Texas

  • Cedar Health Research - Euless

    Euless, Texas

  • Cedar Health Research - Fort Worth

    Fort Worth, Texas

  • Care Access - Houston

    Houston, Texas

  • IMA Clinical Research San Antonio

    San Antonio, Texas

  • FutureMeds - Birmingham

    Birmingham, United Kingdom

  • Layton Medical Centre

    Blackpool, United Kingdom

  • Bradford on Avon Health Centre

    Bradford on Avon, United Kingdom

  • FutureMeds - Liverpool

    Bromborough, United Kingdom

  • Cheadle Community Hospital

    Cheadle, United Kingdom

  • HMC Health Group - Meadows Centre for Health

    Hounslow, United Kingdom

  • St Bartholomew's Medical Centre

    Oxford, United Kingdom

  • Atlantic Medical

    Penzance, United Kingdom

  • The Adam Practice

    Poole, United Kingdom

  • Woodstock Bower Surgery

    Rotherham, United Kingdom

  • Rame Group Practice

    Torpoint, United Kingdom

  • Albany House Medical Centre

    Wellingborough, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.